# Hemophilia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hemophilia

> 4 upcoming FDA catalysts in hemophilia: Qfitlia™ (fitusiran, SNY) on Mar to Jun 2027 (topline data readout); Qfitlia™ (fitusiran, SNY) on March 2027 (primary completion); Qfitlia™ (fitusiran, SNY) on Aug to Nov 2029 (topline data readout); Qfitlia™ (fitusiran, SNY) on August 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 4, 2026 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | completed | "NCT03974113 (Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03974113)) |
| Aug to Nov 2026 | [Qfitlia™ (fitusiran) topline data readout](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT03974113 (Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03974113)) |
| September 14, 2026 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | completed | "NCT03754790 (Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-14 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03754790)) |
| Sep to Dec 2026 | [Qfitlia™ (fitusiran) topline data readout](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT03754790 (Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-14 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03754790)) |
| Mar to Jun 2027 | [Qfitlia™ (fitusiran) topline data readout](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT05662319 (A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662319)) |
| March 2027 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT05662319 (A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662319)) |
| Aug to Nov 2029 | [Qfitlia™ (fitusiran) topline data readout](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT07285460 (A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285460)) |
| August 2029 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT07285460 (A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285460)) |

## Drugs

- [Qfitlia™ (fitusiran)](https://sec-api.dev/pdufa/fitusiran) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hemophilia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hemophilia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hemophilia

```bibtex
@misc{secapidev_indications_hemophilia_20261116,
  title        = {Hemophilia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hemophilia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hemophilia_20261116","title":"Hemophilia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hemophilia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
